These results were later supported by a study carried out using a mouse model of nonalcoholic fatty liver disease (NAFLD), where Hsp90 overexpression resulted in increased PPARγ signaling, while inhibition of Hsp90 reduced PPARγ protein levels and signaling [146]. Here, HSP90AA1 is linked to metabolic dysfunction-associated steatotic liver disease.